Latest From Athersys Inc.
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Activity in Japan's cell and regenerative therapy space continues apace as venture starts trial with lead development asset for acute respiratory distress syndrome.
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- BTHC VI Inc.
- North America
- Parent & Subsidiaries
- Athersys Inc.
- Senior Management
Gil Van Bokkelen, PhD, Chmn. & CEO
John Harrington, PhD, EVP, CSO
Laura Campbell, SVP, Fin.
William Lehmann, JD, President and COO
Manal Morsy, MD, PhD, SVP, Head of RA
Robert Mays, PhD, VP Regenerative Medicine. Head Neuroscience
Anthony Ting, PhD, VP Regenerative Medicine. Head Cardiopulmonary
Raymond Starling, PhD, VP, Clinical Dev & Ops
- Contact Info
Phone: (216) 431-9900
3201 Carnegie Ave.
Cleveland, OH 44115-2634
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.